Purpose

To present current expert practice patterns and to formulate a consensus for management of HSV and VZV AU by uveitis specialists worldwide.

Methods

A two-round online modified Delphi survey with masking of the study team was conducted. Responses were collected from seventy-six international uveitis experts from 21 countries. Current practices in the diagnosis and treatment of HSV and VZV AU were identified. A working group (The Infectious Uveitis Treatment Algorithm Network [TITAN]) developed data into consensus guidelines. Consensus is defined as a particular response toward specific question meeting ≥ 75% of agreement or IQR ≤1 when a Likert scale is used.

Results

Unilaterality, increased intraocular pressure (IOP), decreased corneal sensation and diffuse or sectoral iris atrophy are quite specific for HSV or VZV AU from consensus opinion. Sectoral iris atrophy is characteristic of HSV AU. Treatment initiation is highly variable but most experts preferred valacyclovir owing to simpler dosing. Topical corticosteroids and beta-blockers should be used if necessary. Resolution of inflammation and normalization of IOP are clinical endpoints.

Conclusions

Consensus statements were reached on several aspects of diagnosis, choice of initial treatment and treatment endpoints for HSV and VZV AU. Treatment duration and management of recurrences varied between experts.